Cholestor Warnings

It is contraindicated in pregnant or nursing women.
It is contraindicated in patients with hepatic impairments.
If muscle pain of calf, back or entire body occur during the administration of rosuvastatin, the drug should be discontinued and consult a physician.
The liver function tests should be performed before and at 6 and 12 weeks after initiation of rosuvastatin therapy and periodically (e.g., semiannually) thereafter. If increases in AST or ALT concentrations of 3 times the upper limit of normal or higher persist, the dosage of rosuvastatin should be discontinued and consult a physician.
Caution should be exercised when digoxin, warfarin are given in conjunction with rosuvastatin as the serum concentration of these drugs may be enhanced by concomitant administration of rosuvastatin.
The risk of myopathy and rhabdomyolysis may be increased in patients receiving rosuvastatin concomitant with certain drugs, including certain azole antifungals (e.g. ketoconazole, itraconazole), macrolide antibiotics (e.g. erythromycin, clarithromycin), HIV protease inhibitors (e.g. indinavir, ritonavir, nelfinavir, saquinavir), verapamil, diltiazem, gemfibrozil, nicotinic acid, cyclosporine and amiodarone.
The risk of rhabdomyolysis may be increased in certain groups of patients' e.g. geriatric patient, the patient with liver or renal functional impairment, the patient with chronic alcoholism, hypothyroidism or using high dose.
Caution should be exercised when colchicine is given, especially in the elderly or patients with renal impairment.This combination will increase the risk of myopathy or rhabdomyolysis.
This medicine may cause the risk of hyperglycemia.